Format

Send to

Choose Destination
SLAS Discov. 2019 Jun;24(5):505-514. doi: 10.1177/2472555219838210. Epub 2019 Apr 29.

A Perspective on Extreme Open Science: Companies Sharing Compounds without Restriction.

Author information

1
1 Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Abstract

Although the human genome provides the blueprint for life, most of the proteins it encodes remain poorly studied. This perspective describes how one group of scientists, in seeking new targets for drug discovery, used open science through unrestricted sharing of small molecules to shed light on dark matter of the genome. Starting initially with a single pharmaceutical company before expanding to multiple companies, a precedent was established for sharing published kinase inhibitors as chemical tools. The integration of open science and kinase chemogenomics has supported the study of many new potential drug targets by the scientific community.

KEYWORDS:

compound repositories; kinases; medicinal chemistry; phenotypic drug discovery

PMID:
31034310
PMCID:
PMC6624833
[Available on 2020-06-01]
DOI:
10.1177/2472555219838210

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center